Published in Clin Cancer Res on April 07, 2009
T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther (2010) 3.29
Clinical radioimmunotherapy--the role of radiobiology. Nat Rev Clin Oncol (2011) 1.10
Carcinoembryonic antigen interacts with TGF-{beta} receptor and inhibits TGF-{beta} signaling in colorectal cancers. Cancer Res (2010) 0.98
Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy. Semin Nucl Med (2010) 0.96
The immune response to tumors as a tool toward immunotherapy. Clin Dev Immunol (2011) 0.91
Exploring Glycan Markers for Immunotyping and Precision-targeting of Breast Circulating Tumor Cells. Arch Med Res (2015) 0.78
Combination of antibody targeting and PTD-mediated intracellular toxin delivery for colorectal cancer therapy. J Control Release (2014) 0.77
Novel anticarcinoembryonic antigen antibody-drug conjugate has antitumor activity in the existence of soluble antigen. Cancer Med (2017) 0.75
MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med (1996) 3.32
Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol (2002) 2.41
Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J Clin Oncol (1999) 2.19
Gemcitabine-induced radiation recall. Int J Radiat Oncol Biol Phys (2002) 1.49
Transient CEA increase at start of oxaliplatin combination therapy for metastatic colorectal cancer. Acta Oncol (2004) 1.45
Basic immunology of antibody targeted radiotherapy. Int J Radiat Oncol Biol Phys (2006) 1.41
Radiation concurrent with gemcitabine for locally advanced head and neck cancer: a phase I trial and intracellular drug incorporation study. J Clin Oncol (2001) 1.27
Difluorodeoxycytidine (dFdC)--gemcitabine: a phase I study. Invest New Drugs (1992) 1.21
In vivo quantitation of lesion radioactivity using external counting methods. Med Phys (1976) 1.18
A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer. Clin Cancer Res (2003) 1.05
Gemcitabine safety overview. Semin Oncol (1996) 1.02
Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma. Clin Cancer Res (2005) 1.00
Radiosensitizing potential of gemcitabine (2',2'-difluoro-2'-deoxycytidine) within the cell cycle in vitro. Int J Radiat Oncol Biol Phys (1998) 0.98
Targeted radionuclide therapy for solid tumors: an overview. Int J Radiat Oncol Biol Phys (2006) 0.96
Combination therapy with Pretarget CC49 radioimmunotherapy and gemcitabine prolongs tumor doubling time in a murine xenograft model of colon cancer more effectively than either monotherapy. Clin Cancer Res (2003) 0.95
A phase I trial of (90)Y-DOTA-anti-CEA chimeric T84.66 (cT84.66) radioimmunotherapy in patients with metastatic CEA-producing malignancies. Cancer Biother Radiopharm (2006) 0.95
Optimization of radioimmunotherapy of solid tumors: biological impediments and their modulation. Clin Cancer Res (2007) 0.92
A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies. Clin Cancer Res (2000) 0.91
Pharmacokinetic modeling and absorbed dose estimation for chimeric anti-CEA antibody in humans. J Nucl Med (1997) 0.90
Changes in peripheral blood lymphocyte subsets in patients undergoing radiotherapy. Int J Radiat Biol (1999) 0.90
Clinical evaluation of indium-111-labeled chimeric anti-CEA monoclonal antibody. J Nucl Med (1997) 0.90
A schema for absorbed-dose calculations for biologically-distributed radionuclides. J Nucl Med (1968) 0.90
Radiosensitization by gemcitabine. Oncology (Williston Park) (1999) 0.89
Systemic targeted radionuclide therapy: potential new areas. Int J Radiat Oncol Biol Phys (2006) 0.89
A phase I trial of a rhenium 186-labeled monoclonal antibody administered intraperitoneally in ovarian carcinoma: toxicity and clinical response. Obstet Gynecol (1993) 0.87
Tumor marker CEA in monitoring of response to tegafur-uracil and folinic acid in patients with metastatic colorectal cancer. Hepatogastroenterology (2002) 0.81
Chemotherapy-induced carcinoembryonic antigen surge in patients with metastatic colorectal cancer. Oncology (2006) 0.80
Impact of radiotherapy with and without concurrent cisplatin on lymphocyte subpopulations in cervical cancer patients. Anticancer Res (2005) 0.80
Phase I trial dosing of gemcitabine and concurrent involved field irradiation in patients with localized pancreatic carcinomas. J Clin Oncol (1999) 0.78
Gemcitabine and radiation therapy for non-small cell lung cancer. Semin Oncol (1998) 0.77
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood (2008) 7.01
Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering. Ann Intern Med (2009) 3.83
T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood (2002) 3.57
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood (2012) 2.97
In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol (2009) 2.76
Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res (2004) 2.54
Cost-effectiveness of hypertension therapy according to 2014 guidelines. N Engl J Med (2015) 2.47
Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains. Hum Gene Ther (2007) 2.23
Small cell lung cancer. J Natl Compr Canc Netw (2013) 2.04
A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res (2013) 1.90
Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J Clin Oncol (2009) 1.70
The role of adjuvant radiation in uterine sarcomas. Int J Radiat Oncol Biol Phys (2009) 1.69
Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy. J Clin Oncol (2004) 1.66
S1PR1-STAT3 signaling is crucial for myeloid cell colonization at future metastatic sites. Cancer Cell (2012) 1.64
A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study. Clin Cancer Res (2008) 1.60
Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging. Cancer Res (2005) 1.54
Actual dose variation of parotid glands and spinal cord for nasopharyngeal cancer patients during radiotherapy. Int J Radiat Oncol Biol Phys (2008) 1.47
Forecasting the future economic burden of current adolescent overweight: an estimate of the coronary heart disease policy model. Am J Public Health (2009) 1.38
Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma. J Clin Oncol (2006) 1.37
Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes. Mol Ther (2004) 1.36
Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. J Thorac Oncol (2009) 1.28
TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo. Blood (2013) 1.27
A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer. J Thorac Oncol (2011) 1.24
Overcoming barriers to cancer pain management: an institutional change model. J Pain Symptom Manage (2007) 1.21
Organ sparing by conformal avoidance intensity-modulated radiation therapy for anal cancer: dosimetric evaluation of coverage of pelvis and inguinal/femoral nodes. Int J Radiat Oncol Biol Phys (2005) 1.20
TLR9 signaling in the tumor microenvironment initiates cancer recurrence after radiotherapy. Cancer Res (2013) 1.14
Intratumoral immunocytokine treatment results in enhanced antitumor effects. Cancer Immunol Immunother (2008) 1.13
Biophotonic cytotoxicity assay for high-throughput screening of cytolytic killing. J Immunol Methods (2005) 1.13
Helical tomotherapy for radiotherapy in esophageal cancer: a preferred plan with better conformal target coverage and more homogeneous dose distribution. Med Dosim (2007) 1.10
Low-dose valproic acid enhances radiosensitivity of prostate cancer through acetylated p53-dependent modulation of mitochondrial membrane potential and apoptosis. Mol Cancer Res (2011) 1.10
Barriers to pain assessment and management in cancer survivorship. J Cancer Surviv (2008) 1.09
Activation of nuclear factor kappaB in radioresistance of TP53-inactive human keratinocytes. Cancer Res (2002) 1.08
Small cell lung cancer. J Natl Compr Canc Netw (2011) 1.07
Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097). J Thorac Oncol (2010) 1.07
Intracellular processing of immunostimulatory CpG-siRNA: Toll-like receptor 9 facilitates siRNA dicing and endosomal escape. J Control Release (2013) 1.07
Radiotherapy and extent of surgical resection in retroperitoneal soft-tissue sarcoma: multi-institutional analysis of 261 patients. J Surg Oncol (2010) 1.07
Combining adoptive cellular and immunocytokine therapies to improve treatment of B-lineage malignancy. Cancer Res (2007) 1.07
Small cell lung cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw (2006) 1.06
An anti-CD20-IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma. Blood (2005) 1.06
HDAC inhibitor, valproic acid, induces p53-dependent radiosensitization of colon cancer cells. Cancer Biother Radiopharm (2009) 1.06
Imaging immune response in vivo: cytolytic action of genetically altered T cells directed to glioblastoma multiforme. Clin Cancer Res (2008) 1.06
New standards and implications for improving the quality of supportive oncology practice. J Clin Oncol (2008) 1.05
Humanization of the anti-CEA T84.66 antibody based on crystal structure data. Protein Eng Des Sel (2004) 1.05
Palliative care in lung cancer. Surg Clin North Am (2011) 1.05
Preparing New World monkeys for laboratory research. ILAR J (2006) 1.03
Dosimetric comparison of helical tomotherapy treatment and step-and-shoot intensity-modulated radiotherapy of retroperitoneal sarcoma. Radiother Oncol (2006) 1.03
Imaging glioma extent with 131I-TM-601. J Nucl Med (2005) 1.03
A versatile bifunctional chelate for radiolabeling humanized anti-CEA antibody with In-111 and Cu-64 at either thiol or amino groups: PET imaging of CEA-positive tumors with whole antibodies. Bioconjug Chem (2007) 1.02
Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics. Clin Cancer Res (2003) 1.00
Development and application of CD19-specific T cells for adoptive immunotherapy of B cell malignancies. Blood Cells Mol Dis (2004) 1.00
Impact of drug therapy, radiation dose, and dose rate on renal toxicity following bone marrow transplantation. Int J Radiat Oncol Biol Phys (2008) 1.00
Preclinical results of camptothecin-polymer conjugate (IT-101) in multiple human lymphoma xenograft models. Clin Cancer Res (2009) 1.00
Dosimetric comparisons of helical tomotherapy treatment plans and step-and-shoot intensity-modulated radiosurgery treatment plans in intracranial stereotactic radiosurgery. Int J Radiat Oncol Biol Phys (2006) 0.97
Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody. J Clin Oncol (2005) 0.96
Improved biodistribution and radioimmunoimaging with poly(ethylene glycol)-DOTA-conjugated anti-CEA diabody. Bioconjug Chem (2006) 0.95
A phase I trial of (90)Y-DOTA-anti-CEA chimeric T84.66 (cT84.66) radioimmunotherapy in patients with metastatic CEA-producing malignancies. Cancer Biother Radiopharm (2006) 0.95
Quantitative serial imaging of an 124I anti-CEA monoclonal antibody in tumor-bearing mice. Cancer Biother Radiopharm (2008) 0.95
Symptom concerns and resource utilization in patients with lung cancer. J Palliat Med (2007) 0.95
First-line systemic therapy practice patterns and concordance with NCCN guidelines for patients diagnosed with metastatic NSCLC treated at NCCN institutions. J Natl Compr Canc Netw (2012) 0.94
Biodistribution and tumor imaging of an anti-CEA single-chain antibody-albumin fusion protein. Nucl Med Biol (2008) 0.94
A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California cancer consortium trial. J Thorac Oncol (2012) 0.94
Implementing the Fatigue Guidelines at one NCCN member institution: process and outcomes. J Natl Compr Canc Netw (2007) 0.93
Dosimetric study and verification of total body irradiation using helical tomotherapy and its comparison to extended SSD technique. Med Dosim (2009) 0.93
Suberoylanilide hydroxamic acid as a radiosensitizer through modulation of RAD51 protein and inhibition of homology-directed repair in multiple myeloma. Mol Cancer Res (2012) 0.93
Acute toxicity in definitive versus postprostatectomy image-guided radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys (2007) 0.93
Preoperative versus postoperative radiotherapy in soft-tissue sarcoma: multi-institutional analysis of 821 patients. Int J Radiat Oncol Biol Phys (2010) 0.92
Reducing patient barriers to pain and fatigue management. J Pain Symptom Manage (2010) 0.91
An interdisciplinary care approach for integration of palliative care in lung cancer. Clin Lung Cancer (2008) 0.91
Quality of life and barriers to symptom management in colon cancer. Eur J Oncol Nurs (2011) 0.90
Phase II trial of bryostatin-1 in combination with cisplatin in patients with recurrent or persistent epithelial ovarian cancer: a California cancer consortium study. Invest New Drugs (2010) 0.90
Dosimetric study of volumetric modulated arc therapy fields for total marrow irradiation. Radiother Oncol (2011) 0.90
Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium. Lung Cancer (2012) 0.89
Setup variations in radiotherapy of esophageal cancer: evaluation by daily megavoltage computed tomographic localization. Int J Radiat Oncol Biol Phys (2007) 0.89
Total marrow irradiation: a new ablative regimen as part of tandem autologous stem cell transplantation for patients with multiple myeloma. Clin Cancer Res (2010) 0.89
Pitch, roll, and yaw variations in patient positioning. Int J Radiat Oncol Biol Phys (2006) 0.89
Management of Anorexia-Cachexia in Late Stage Lung Cancer Patients. J Hosp Palliat Nurs (2012) 0.89
Cancer-related fatigue: role of oncology nurses in translating National Comprehensive Cancer Network assessment guidelines into practice. Clin J Oncol Nurs (2008) 0.88
Monodispersed DOTA-PEG-conjugated anti-TAG-72 diabody has low kidney uptake and high tumor-to-blood ratios resulting in improved 64Cu PET. J Nucl Med (2010) 0.88
Intracerebral CpG immunotherapy with carbon nanotubes abrogates growth of subcutaneous melanomas in mice. Clin Cancer Res (2012) 0.88
Matched-cohort analysis of autologous hematopoietic cell transplantation with radioimmunotherapy versus total body irradiation-based conditioning for poor-risk diffuse large cell lymphoma. Biol Blood Marrow Transplant (2011) 0.87
Tandem high-dose chemotherapy followed by autologous transplantation in patients with locally advanced or metastatic sarcoma. Anticancer Res (2009) 0.87
T-cell genetic modification for re-directed tumor recognition. Cancer Chemother Biol Response Modif (2005) 0.86
Predictors of finding benefit after lung cancer diagnosis. Psychooncology (2011) 0.86
Impact of reduced k-space acquisition on pathologic detectability for volumetric MR spectroscopic imaging. J Magn Reson Imaging (2013) 0.85
Phase I trial of menadiol diphosphate (vitamin K3) in advanced malignancy. Invest New Drugs (2005) 0.85
Effectiveness of a clinical intervention to eliminate barriers to pain and fatigue management in oncology. J Palliat Med (2011) 0.85
A series of anti-CEA/anti-DOTA bispecific antibody formats evaluated for pre-targeting: comparison of tumor uptake and blood clearance. Protein Eng Des Sel (2012) 0.85
Impact of the number of resected and involved lymph nodes on esophageal cancer survival. J Surg Oncol (2009) 0.83
A pretherapy biodistribution and dosimetry study of indium-111-radiolabeled trastuzumab in patients with human epidermal growth factor receptor 2-overexpressing breast cancer. Cancer Biother Radiopharm (2010) 0.83
Combined radioimmunotherapy and chemotherapy of breast tumors with Y-90-labeled anti-Her2 and anti-CEA antibodies with taxol. Bioconjug Chem (2005) 0.82
Cell membrane-specific epitopes on CD30: Potentially superior targets for immunotherapy. Proc Natl Acad Sci U S A (2005) 0.81
T2-weighted spine imaging with a fast three-point dixon technique: comparison with chemical shift selective fat suppression. J Magn Reson Imaging (2004) 0.81
Treatment outcomes for patients with chloroma receiving radiation therapy. J Med Imaging Radiat Oncol (2014) 0.80